Gapping up
In reaction to strong earnings/guidance: BURL +12.3%, ELOS +9.7%, HZNP +8.8%, LULU +8.7%, UCTT +5%, ACLS +4.2%, TACO +3.7%, SAP +3%, ABMD +2.5%, EXPR +2.5%, BIG +2.4%, CAH +1.7%, CTSH +1.6%, ASNA +0.7%, CRAY +0.6%, XENT +0.4%
M&A news: APOL +19.7% (following report that Apollo Global Management (APO) nearing deal to buy Apollo Education), PHG +2.8% (Sky News report of potential Melrose bid for lighting unit), SNN +1.8% (announces the acquisition of BST-CarGel)
Select EU related names showing strength: LUX +4.1%, NVO +2.6%, ABB +2%, UN +1.8%, SNY +1.5%, ASML +1.3%, STM +1.1%
Other news: SNOW +28.2% (announces modified 'Dutch auction' self-tender offer to purchase up to $50 mln of common stock with cash), BIOC +19.7% (entered into an agreement with Blue Cross Blue Shield of Illinois allowing its members access to Biocept's menu for liquid biopsy testing), BLRX +17.5% (announces collaboration with Merck (MRK) on Phase 2 study investigating BioLineRx's BL-8040 in combination with KEYTRUDA), BCLI +15.1% (Jama Neurology releases Promising Data from ALS Clinical Trial), PSTI +9.5% (receives FDA approval to begin PLX-R18 clinical trial), CLLS +8% (announced the publication of a study describing the design and development of a new CAR architecture with an integrated switch-on system that permits control over CAR T-cell functions),XONE +8% (to raise ~$13 mln in gross proceeds in a registered direct offering of common shares from its Chairman and CEO), AVP +6.1% (modest rebound following last week's decline), TEDU +3.8% (Strategic Partnership with Alibaba Cloud Computing Co), SUNE +3.3% (modest rebound following last week's decline), BAS +2.8% (reports December op data; expect Q4 revenues to be at the higher end of the range that previously announced), PODD +2.3% (entered into development agreement with Eli Lilly (LLY) for OmniPod delivery of U200 concentrated insulin), TSLA +2% (trading higher with the mkt), SBUX +1.6% (on-track w/ 2K stores in China), JBLU +1.3% (in symp with AAL), NFLX +1% (trading higher with the mkt), AAL +1% (reports Dec traffic)
Analyst comments: SHPG +5.5% (upgraded to Outperform from Neutral at Credit Suisse), CIEN +3.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley), AAPL +1.8% (upgraded to Buy from Neutral at BofA/Merrill), INTC +1.7% (upgraded to Buy at Mizuho), KO +1.6% (upgraded to Buy from Hold at Stifel), AMZN +1.2% (target raised to $800 from $777 at Credit Suisse)
In reaction to strong earnings/guidance: BURL +12.3%, ELOS +9.7%, HZNP +8.8%, LULU +8.7%, UCTT +5%, ACLS +4.2%, TACO +3.7%, SAP +3%, ABMD +2.5%, EXPR +2.5%, BIG +2.4%, CAH +1.7%, CTSH +1.6%, ASNA +0.7%, CRAY +0.6%, XENT +0.4%
M&A news: APOL +19.7% (following report that Apollo Global Management (APO) nearing deal to buy Apollo Education), PHG +2.8% (Sky News report of potential Melrose bid for lighting unit), SNN +1.8% (announces the acquisition of BST-CarGel)
Select EU related names showing strength: LUX +4.1%, NVO +2.6%, ABB +2%, UN +1.8%, SNY +1.5%, ASML +1.3%, STM +1.1%
Other news: SNOW +28.2% (announces modified 'Dutch auction' self-tender offer to purchase up to $50 mln of common stock with cash), BIOC +19.7% (entered into an agreement with Blue Cross Blue Shield of Illinois allowing its members access to Biocept's menu for liquid biopsy testing), BLRX +17.5% (announces collaboration with Merck (MRK) on Phase 2 study investigating BioLineRx's BL-8040 in combination with KEYTRUDA), BCLI +15.1% (Jama Neurology releases Promising Data from ALS Clinical Trial), PSTI +9.5% (receives FDA approval to begin PLX-R18 clinical trial), CLLS +8% (announced the publication of a study describing the design and development of a new CAR architecture with an integrated switch-on system that permits control over CAR T-cell functions),XONE +8% (to raise ~$13 mln in gross proceeds in a registered direct offering of common shares from its Chairman and CEO), AVP +6.1% (modest rebound following last week's decline), TEDU +3.8% (Strategic Partnership with Alibaba Cloud Computing Co), SUNE +3.3% (modest rebound following last week's decline), BAS +2.8% (reports December op data; expect Q4 revenues to be at the higher end of the range that previously announced), PODD +2.3% (entered into development agreement with Eli Lilly (LLY) for OmniPod delivery of U200 concentrated insulin), TSLA +2% (trading higher with the mkt), SBUX +1.6% (on-track w/ 2K stores in China), JBLU +1.3% (in symp with AAL), NFLX +1% (trading higher with the mkt), AAL +1% (reports Dec traffic)
Analyst comments: SHPG +5.5% (upgraded to Outperform from Neutral at Credit Suisse), CIEN +3.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley), AAPL +1.8% (upgraded to Buy from Neutral at BofA/Merrill), INTC +1.7% (upgraded to Buy at Mizuho), KO +1.6% (upgraded to Buy from Hold at Stifel), AMZN +1.2% (target raised to $800 from $777 at Credit Suisse)